Cephaloridine in vitro toxicity and accumulation in renal slices from normoglycemic and diabetic rats.
Previous work has shown a reduction in cephaloridine nephrotoxicity in a diabetic rat model. The following studies examined in vitro cephaloridine toxicity in renal slices from normoglycemic and diabetic Fischer 344 rats. Diabetes was induced by acute intraperitoneal injection of 35 mg/kg streptozotocin. Renal cortical slices were isolated from normoglycemic and diabetic animals. Tissues were exposed to 0-5 mM cephaloridine for 15-120 min. Pyruvate-directed gluconeogenesis was diminished in all groups exposed to 2-5 mM cephaloridine for 60-120 min. Leakage of lactate dehydrogenase (LDH) was apparent only in the normoglycemic group in the presence of 4-5 mM cephaloridine for 120 min. LDH leakage was not increased at any cephaloridine concentration in the diabetic tissue. Total glutathione levels were compared in renal cortical slices exposed to cephaloridine for 30-120 min. Baseline values for glutathione were comparable between normoglycemic and diabetic tissue suggesting that the mechanism for reduced toxicity was not due to higher glutathione levels in diabetic tissue. Total glutathione levels were diminished more rapidly in normoglycemic than diabetic tissue by incubation with 5 mM cephaloridine. Comparison of cephaloridine accumulation indicated that diabetic tissue accumulated less cephaloridine than the normoglycemic group when tissues were incubated with 0-2 mM cephaloridine. However, renal slice accumulation was similar between normoglycemic and diabetic groups following in vitro incubation with 4-5 mM cephaloridine. These results suggest that the mechanism for reduced in vitro cephaloridine toxicity in diabetic tissue cannot be limited to differences in accumulation and must include an unidentified cellular component.
Valentovic
M
M
Department of Pharmacology, Marshall University School of Medicine, Huntington, West Virginia, 25704-9388, USA.
Ball
J G
JG
Rogers
B A
BA
Meadows
M K
MK
Harmon
R C
RC
Moles
J
J
D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000633:toxicity*; D002509:Cephaloridine / Q000493:pharmacokinetics* / Q000633:toxicity*; D003921:Diabetes Mellitus, Experimental / Q000473:pathology*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D005943:Gluconeogenesis / Q000187:drug effects; D005978:Glutathione / Q000378:metabolism; D066298:In Vitro Techniques; D007668:Kidney / Q000378:metabolism / Q000473:pathology*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008297:Male; D051381:Rats; D011916:Rats, Inbred F344; D012079:Renal Circulation / Q000187:drug effects
D000900:Anti-Bacterial Agents; D007770:L-Lactate Dehydrogenase; D005978:Glutathione; D002509:Cephaloridine